Search

everythinglearnresearchcommunity

for

Search:↓

The user is considering adding Alfatradiol or Pyralutamide to their current hair loss treatment of oral Dutasteride and Minoxidil. They are seeking advice on experiences and purchasing options for these products in the US.

A trial of verteporfin for hair regeneration, with pictures comparing the original and current status, as well as links to other resources discussing the efficacy of this treatment in combination with Minoxidil, Finasteride, and RU58841.

The user is using RU58841, Minoxidil, and weekly microneedling for hair loss, having stopped finasteride due to side effects like low libido and depression. They are considering dutasteride as an alternative but are cautious due to past experiences with DHT blockers.

Dutasteride is associated with increased blood glucose, HbA1c, LDL cholesterol, and liver enzyme activity, potentially leading to diabetes, NAFLD, and liver metabolism changes. The conversation highlights concerns about these adverse effects and calls for more studies, including on finasteride.

The conversation discusses the potential of topical rapamycin, metformin, and alpha-ketoglutarate (a-KG) for hair growth, with skepticism expressed about their effectiveness based on personal experience and existing use. It also mentions AICAR, known as cardarine or GW, which is not suitable for long-term use due to cancer risks in animal studies and its similarity to metformin.

A 30-year-old woman with androgenetic alopecia is considering bicalutamide to slow hair loss but is concerned about its impact on muscle growth due to its anti-androgen effects. Alternatives suggested include dutasteride, spironolactone, RU58841, and minoxidil, with concerns about bicalutamide's side effects.

The conversation is about the release of a new phase 3 clinical trial for a year and questioning if the results of the 6-month clinical trials will be shown this quarter. The specific treatment discussed is Pyrilutamide.

User gained hair with topical minoxidil and finasteride, then experienced shedding after starting pyrilutamide. After 12 weeks, new hairs grew and existing hairs thickened, hoping for more improvement in a year.

The conversation discusses hair loss treatments, specifically Minoxidil, finasteride, and RU58841. It also inquires about the timeline for the GT20029 phase 3 trial by Kintor.

The user is experiencing hair loss and has been using RU58841 but is considering pyrilutamide and minoxidil, avoiding finasteride due to side effects. Another user suggests finasteride or dutasteride as essential, possibly in topical form, while dismissing saw palmetto as ineffective.

Kintor is producing a cosmetic with KX826, starting at 0.5% concentration and moving to 1%. The 0.5% concentration wasn't as effective as minoxidil and finasteride, but the 1% concentration shows promise.

Breezula shows promising hair growth results, with up to 539% increase in hair count compared to placebo, and regulatory submissions are planned in the US and EU. Users are cautiously optimistic, noting the potential for Breezula to replace finasteride by targeting DHT without systemic effects.

Researching the release of phase 2 trials for pyrilutamide, a potential hair loss treatment, and discussing other treatments such as Minoxidil, Finasteride, and RU58841.

User experienced reduced hair loss with 15mg RU in Serioxyl but had concerning chest pain. Others suggested consulting a doctor or lowering the dose.

The user experienced significant hair regrowth with 0.5mg oral finasteride daily, despite a minoxidil allergy, and reported no side effects. They also used a keto shampoo and were satisfied with the results.

The user has been using minoxidil and finasteride for hair loss without positive results and switched to dutasteride 1.5 months ago. They suspect seborrheic dermatitis might be affecting the effectiveness of these treatments.

Kintor is testing Pyrilutamide with Minoxidil for hair loss. Users are skeptical about its effectiveness and concerned about limited treatment options if this fails.

The user experienced hair regrowth using 1 mg finasteride and 5% minoxidil for 4 months, then switched to 0.5 mg dutasteride, 1.5 mg minoxidil, microneedling, and ketoconazole shampoo for 8 months. They noticed significant improvement after switching to dutasteride.

A user shared their experience with hair loss treatments, using minoxidil, pyrilutamide, alfatrodial, and nizoral to improve hair density and thickness. They reported positive results without side effects and emphasized the importance of consistency with topical treatments.

The user, on testosterone replacement therapy, found finasteride and minoxidil ineffective for hair loss. They are trying a new topical gel with dutasteride, tretinoin, and a higher concentration of minoxidil, and plan to document the results.

FOL-005 claims to be more effective than Minoxidil and Finasteride but lacks anti-DHT properties, leading to potential reduced efficacy over time. Concerns are raised about misleading marketing and the safety of alternative treatments like Pyrilutamide and Clascoterone.

Dutasteride and finasteride are not effectively stopping hair loss for some users, despite long-term use. Some are considering or using RU58841, pyrilutamide, and other treatments like microneedling, while also managing seborrheic dermatitis with diet and topical solutions.

Combining pyrilutamide and alfatradiol might be as effective as finasteride for hair maintenance. The user plans to try this combination alongside minoxidil and keto shampoo, hoping for improved hair thickness.

Breezula's phase 3 results are expected soon, with discussions on the effectiveness of androgen receptor antagonists like spironolactone and the potential of GT20029. Users express skepticism about new treatments and discuss the complexities of male pattern baldness, often relying on finasteride despite its side effects.

RU58841 is used without finasteride by some due to side effects, with mixed results. Users report combining RU58841 with minoxidil and adjusting finasteride doses to manage hair loss.

The user started using a hair loss treatment called pyrilutamide and experienced mild chest discomfort and tightness, similar to previous side effects from RU58841. They plan to reduce the dosage due to these side effects and will provide an update on the results in 1-2 months.

KX826 shows promise as a hair loss treatment with a 10% increase in hair count, but concerns about Kintor's marketing practices and the systemic effects of treatments like GT20029 and RU58841 remain. Users express skepticism and hope, with some preferring traditional treatments like finasteride and minoxidil.

The conversation is about someone experiencing continued hair loss despite using Pyrilutamide and considering the need for more time or better quality control for the treatment. Another person suggests waiting for the drug to be officially approved due to potential quality issues with current products.

The user has been using finasteride, minoxidil, and nizoral for hair loss but hasn't seen regrowth, only maintenance. They are considering switching to dutasteride, which is believed to be more effective, but are concerned about potential side effects.

The conversation discusses hair loss treatments using oral minoxidil, oral dutasteride, and mesotherapy dutasteride, showing impressive 6-month results. The user wishes these treatments were available in the U.S.